Dicot's clinical phase 1 study starts today

Press release: Uppsala, August 25, 2023. Today is the formal start of Dicot's clinical phase 1 study with the drug candidate LIB-01 as the first screening visit is being performed. The study is a placebo-controlled trial with the primary objective to evaluate the safety profile in humans.

Last week, Dicot received approval from the relevant authorities to start a clinical phase 1 trial. Dicot's partner CTC, which will conduct the study, began recruiting participants immediately. Since all other preparations were completed, the study can start today, just over a week after the approval. It commences with the first of two screening visits to identify participants for the study's first dose group. Screening is the process where research applicants are examined and selected based on a variety of study specific criteria.

As Dicot previously announced, this is a placebo-controlled phase 1 clinical trial with the primary objective to evaluate LIB-01's safety profile in humans. The trial is double-blind, meaning that neither clinic staff who administer the study drug, nor participants, know who is receiving LIB-01 and who is receiving placebo.

"We are proud and happy that everything has gone according to plan and that we were able to start so quickly after the approval from the authorities. Now a completely new chapter in the development of LIB-01 begins. We expect that the first results from the study can be presented during the spring of 2024," says Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.